SecSonar.com

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

C4 Therapeutics, Inc. (CCCC) is a Biotechnology company based in US with a market capitalization of $367.8M. Revenue grew 1.0% year-over-year and free cash flow was negative at -$99.3M. This page tracks CCCC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 110 employees · IPO Oct 2, 2020

Valuation

Valuation & price

$3.56 · as of May 17, 2026 · -23.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.43

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.38$2.95$1.52Jul 25Dec 25Jul 26Jul 7, 25$1.52Jul 9, 25$2.02Jul 11, 25$2.23Jul 15, 25$2.11Jul 17, 25$2.18Jul 21, 25$2.27Jul 23, 25$2.42Jul 25, 25$2.26Jul 29, 25$2.25Jul 31, 25$2.05Aug 4, 25$2.10Aug 6, 25$1.96Aug 11, 25$2.42Aug 13, 25$2.33Aug 15, 25$2.46Aug 19, 25$2.76Aug 21, 25$2.61Aug 25, 25$2.53Aug 27, 25$2.58Aug 29, 25$2.60Sep 3, 25$2.56Sep 5, 25$2.72Sep 9, 25$2.68Sep 11, 25$2.73Sep 16, 25$3.41Sep 18, 25$3.32Sep 22, 25$2.61Sep 24, 25$2.42Sep 26, 25$2.23Sep 30, 25$2.22Oct 2, 25$2.21Oct 6, 25$2.28Oct 8, 25$2.23Oct 10, 25$2.25Oct 14, 25$2.02Oct 16, 25$2.48Oct 21, 25$2.46Oct 23, 25$2.38Oct 27, 25$2.65Oct 29, 25$2.51Oct 31, 25$2.61Nov 4, 25$2.26Nov 6, 25$2.38Nov 10, 25$2.34Nov 12, 25$2.48Nov 14, 25$2.47Nov 18, 25$2.48Nov 20, 25$2.38Nov 25, 25$2.48Nov 28, 25$2.71Dec 2, 25$2.43Dec 4, 25$2.59Dec 8, 25$2.54Dec 10, 25$2.58Dec 12, 25$2.47Dec 16, 25$2.26Dec 18, 25$2.01Dec 22, 25$2.09Dec 24, 25$2.08Dec 29, 25$2.03Jan 2, 26$1.93Jan 6, 26$2.03Jan 8, 26$2.19Jan 12, 26$2.13Jan 14, 26$2.33Jan 16, 26$2.23Jan 21, 26$2.12Jan 23, 26$2.15Jan 27, 26$2.14Jan 29, 26$1.96Feb 2, 26$1.88Feb 4, 26$1.89Feb 9, 26$1.78Feb 11, 26$1.83Feb 13, 26$1.89Feb 18, 26$1.91Feb 20, 26$2.16Feb 24, 26$2.39Feb 26, 26$2.78Mar 2, 26$3.17Mar 4, 26$3.09Mar 6, 26$3.04Mar 10, 26$3.12Mar 12, 26$2.75Mar 17, 26$2.76Mar 19, 26$2.61Mar 23, 26$2.56Mar 25, 26$2.69Mar 27, 26$2.41Mar 31, 26$2.63Apr 2, 26$2.82Apr 7, 26$2.74Apr 9, 26$2.83Apr 13, 26$2.76Apr 15, 26$2.89Apr 17, 26$2.92Apr 22, 26$3.07Apr 24, 26$2.88Apr 28, 26$2.75Apr 30, 26$2.83May 4, 26$3.04May 6, 26$2.93May 8, 26$2.95May 12, 26$3.17May 14, 26$3.63May 18, 26$3.22May 20, 26$3.28May 22, 26$3.56May 28, 26$3.66Jun 1, 26$4.38Jun 3, 26$3.96Jun 5, 26$3.85Jun 9, 26$3.58Jun 11, 26$3.87Jun 15, 26$3.82Jun 17, 26$3.92Jun 22, 26$4.12Jun 24, 26$4.25Jun 26, 26$4.26Jul 2, 26$4.30
$1.5252-week range$4.67
Loading valuation history…

Fundamentals

Key fundamentals

$367.8M

Market cap

1.0%

Revenue growth (YoY)

77.8%

Gross margin

-$99.3M

Free cash flow (USD)

-$188.6M

Net debt

Net cash position

19.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$19.4MFY 2019$21.4MFY 2020$33.2MFY 2021$45.8MFY 2022$31.1MFY 2023$20.8MFY 2024$35.6MFY 2025$35.9M
$19.4M$35.9M

Free cash flow by year

2018 → 2025

FY 2018$-19.7MFY 2019$54.3MFY 2020$-67.9MFY 2021$-88.2MFY 2022$-111.4MFY 2023$-108.5MFY 2024$-65.3MFY 2025$-99.3M
-$19.7M-$99.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 202362.7%FY 2024100.0%FY 202577.8%
100.0%77.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 24, 2026Filing
  • 8-K eventCollaboration AgreementJun 11, 2026Filing
  • 8-K eventPrincipal Accounting Officer ChangeMay 15, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventBy-law AmendmentApr 10, 2026Filing
  • 8-K eventResearch Collaboration AgreementApr 9, 2026Filing

Questions

Frequently asked questions

What is C4 Therapeutics, Inc.'s market cap?

C4 Therapeutics, Inc. (CCCC) has a market capitalization of $367.8M.

What is CCCC's P/E ratio?

A meaningful P/E ratio is not available for CCCC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CCCC's price-to-book (P/B) ratio?

CCCC trades at 1.43 times book value per share.

Are insiders buying CCCC stock?

SEC Form 4 filings show no open-market insider buys at C4 Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PTN

Palatin Technologies, Inc.

$368M

PALI

Palisade Bio, Inc.

$366.3M

RGNX

REGENXBIO Inc.

$365.2M

PBYI

Puma Biotechnology, Inc.

$364.7M

IRD

Opus Genetics, Inc.

$364.7M

KROS

Keros Therapeutics, Inc.

$361.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.